What are Janus kinase inhibitors?
Janus kinase (JAK) inhibitors, also called jakinibs, are small molecules that interrupt the JAK-STAT (Signal Transducer and Activator of Transcription) signalling pathways involved in the pathogenesis of many immune-mediated and/or inflammatory diseases.
What are Janus kinase inhibitors used for?
Janus kinase inhibitors have shown beneficial effects in a variety of immune-mediated conditions affecting the skin, joints, and gastrointestinal tract. JAK inhibitors have also been used successfully in conditions with JAK mutations such as polycythaemia vera, essential thrombocythaemia, and myelofibrosis.
Ruxolitinib was approved by the TGA in Australia in 2013 for the treatment of myelofibrosis.
Baricitinib was TGA-approved in Australia in 2018 for the treatment of rheumatoid arthritis and, in 2021, for moderate to severe atopic dermatitis. Approval for this indication has also been granted by the European Union and Japan. Upadacitinib was approved by Medsafe New Zealand for the treatment of adults and adolescents from the age of 12 years with moderate to severe atopic dermatitis in 2021.
In 2020, delgocitinib cream was approved in Japan for the treatment of atopic dermatitis in adults, and was granted an FDA fast-track designation for the treatment of chronic hand dermatitis.
Use of Janus kinase inhibitors in dermatology
Janus kinase inhibitors have been approved for use in or are currently under investigation for the treatment of:
- Atopic dermatitis
- Topical — delgocitinib, ruxolitinib, tofacitinib
- Oral — baricitinib, tofacitinib, abrocitinib
- Alopecia areata
- Oral — tofacitinib, ruxolitinib, baricitinib
- Topical — ruxolitinib, tofacitinib
- Oral — tofacitinib
- Plaque psoriasis
- Topical — ruxolitinib, brepocitinib
- Oral — tofacitinib, baricitinib, peficitinib, deucravacitinib, filotinib, delgocitinib, itacitinib
- Oral tofacitinib for nail psoriasis
- Other dermatoses
- Chronic hand dermatitis — topical delgocitinib
- Dermatomyositis — oral ruxolitinib, tofacitinib
- Graft versus host disease (GVHD) — oral ruxolitinib, baricitinib, itacitinib — as prophylaxis or treatment of acute or chronic GVHD
- Lichen planus/lichen planopilaris — topical ruxolitinib, oral tofacitinib
- Systemic lupus erythematosus/discoid lupus erythematosus — oral baricitinib, elsubrutinib, upadacitinib
- Granulomatous disorders including sarcoidosis, granuloma annulare, necrobiosis lipoidica — oral tofacitinib
Single case reports or small case series reporting response to JAK inhibitors include: chronic actinic dermatitis, drug hypersensitivity syndrome (DRESS), hypereosinophilic syndrome, morphoea, eosinophilic fasciitis, and hidradenitis suppurativa.
What are the contraindications with Janus kinase inhibitors?
- Hypersensitivity to the drug or any of the product excipients.
- Concurrent biologic agents or other potent immunosuppressant agents.
- Severe liver impairment.
- Pregnancy and lactation: Tofacitinib and baricitinib are rated Category D in Australia as teratogenic effects have been shown in animal studies. They are not recommended for use when breastfeeding. Ruxolitinib crosses the placenta and is excreted in breast milk, so is not recommended in pregnancy (Category C) and lactation.
Tell me more about Janus kinase inhibitors.
The Janus kinase family consists of four receptor-associated tyrosine kinases — JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). When activated, JAKs phosphorylate cell membrane cytokine receptors and intracytoplasmic STATs, thereby modulating gene transcription in the nucleus. The phosphate is provided by ATP, and each JAK and tyrosine kinase recognises a slightly different ATP-binding pocket. Overexpression of these pathways can result in the development of autoimmune disease and malignancies.
JAK inhibitors (JAKi) can be classified as:
- Pan-JAKi — delgocitinib, peficitinib
- JAK1i — oclacitinib, upadacitinib, abrocitinib, itacitinib
- JAK1/2i — baricitinib, ruxolitinib
- JAK1/3i — tofacitinib
- JAK3i — decernotinib, ritlecitinib
- TYK2 inhibitors — deucravacitinib, brepocitinib.
Janus kinase inhibitor signalling pathways
Image from: Singh R, Heron CE, Ghamrawi RI, Strowd LC, Feldman SR. Emerging role of Janus kinase inhibitors for the treatment of atopic dermatitis. Immunotargets Ther. 2020;9:255-72. doi:10.2147/ITT.S229667
What are the benefits of Janus kinase inhibitors?
As Janus kinase inhibitors are small molecules they can be used topically or orally, unlike biologic agents which require administration by injection. They are also significantly cheaper than biologics as JAK inhibitors are chemically synthesised.
What are the disadvantages of Janus kinase inhibitors?
Janus kinase inhibitors may interrupt the signal transduction of multiple cytokine receptors rather than target specific cytokines or cytokine receptors.
For a number of dermatological conditions, clinical trials have shown rapid relapse is common after discontinuation of the JAK inhibitor such as alopecia areata, vitiligo, and psoriasis.
What are the side effects and risks of Janus kinase inhibitors?
As Janus kinase inhibitors alter the immune response, they may be associated with increased risk of serious bacterial, fungal, mycobacterial, and viral infections. Tuberculosis screening should therefore be undertaken before starting treatment with a JAK inhibitor. Reactivation of herpes viruses appears to be common, therefore zoster vaccination prior to commencing treatment is recommended.
Common adverse side effects of JAK inhibitors include:
- Infection of upper respiratory and urinary tracts
- Nausea and diarrhoea.
Selective JAK inhibitors may show unique adverse effect profiles such as cytopenias linked to selective JAK2 inhibition.
Tofacitinib has been used long-term in patients with rheumatoid arthritis:
- Increased lipids may be seen during the first 3 months of treatment, then stabilise
- Malignancies are not increased except for non-melanoma skin cancers
- The TGA in Australia warns high dose (10mg bd) should be used with caution in patients with non-melanoma skin cancer, serious infections, and herpes zoster infection.
In 2021, the FDA issued new updated black box warnings for baricitinib and upadacitinib in line with warnings already in place for tofacitinib. Tofacitinib has been reported to carry increased risks of serious heart-related events, blood clots, and death even at low dose. Although similar adverse events have not yet been reported with baricitinib and upadacitinib, the FDA found the risks have not been adequately evaluated and issued the warning due to the similar mechanisms of action.
If you are not based in New Zealand, we suggest you refer to your national drug approval agency for further information about medicines (eg, the Australian Therapeutic Goods Administration and the US Food and Drug Administration) or a national or state-approved formulary (eg, the New Zealand Formulary and New Zealand Formulary for Children and the British National Formulary and British National Formulary for Children).